TY - JOUR
T1 - Issues concerning life-prolonging treatment in Japan, as considered from attitudes among the legal and medical professions
AU - Iijima, Yoshihiko
N1 - Funding Information:
This survey was conducted under a Grant-in-Aid for Scientific Research C “Examination of the systematic involvement in ethical issues in medical setting”, the AMED Research and Development Grant for Dementia “Construction of an ethical support regime in the construction of a dementia registry system including the pre-clinical period”, and JST Moonshot R&D Grant Number JPMJMS2021. The survey was approved by the ethics committee of the Nagoya University School of Medicine.
Funding Information:
This survey was conducted under a Grant-in-Aid for Scientific Research C ?Examination of the systematic involvement in ethical issues in medical setting?, the AMED Research and Development Grant for Dementia ?Construction of an ethical support regime in the construction of a dementia registry system including the pre-clinical period?, and JST Moonshot R&D Grant Number JPMJMS2021. The survey was approved by the ethics committee of the Nagoya University School of Medicine
Publisher Copyright:
© 2022, Nagoya Journal of Medical Science.All Rights Reserved.
PY - 2022
Y1 - 2022
N2 - In this paper, the author explores the clinical ethical issue of the withdrawal and withholding of life-prolonging treatment, surveying 2,848 lawyers and 2,469 doctors as medical and legal professionals in Japan on a variety of points for discussion. The main survey items are: (1) systems that should be used in the withdrawal and withholding of life-prolonging treatment at the end of life; (2) problems in determining treatment strategy at the end of life; (3) assessment of suspension of life support systems (extubation); and (4) strategies for better end-of-life care. While 42.2% of lawyers cited legislature and judiciary and 54.9% cited academic society guidelines as the system that should respond to the withdrawal and withholding of life-prolonging treatment, 23.3% of doctors cited the legislature and the judiciary, and 65.4% academic society guidelines. In relation to current end-of-life care, 81.3% of lawyers and 69.3% of doctors responded that there was room for improvement. Strategies for doing so included ensuring the transparency of and publishing decision procedures, and notification to government. It is important for medical institutions to normalize end-of-life care by making decisions with reference to guidelines and the like, ensuring the transparency of decision-making procedures, and being managed by a public institution
AB - In this paper, the author explores the clinical ethical issue of the withdrawal and withholding of life-prolonging treatment, surveying 2,848 lawyers and 2,469 doctors as medical and legal professionals in Japan on a variety of points for discussion. The main survey items are: (1) systems that should be used in the withdrawal and withholding of life-prolonging treatment at the end of life; (2) problems in determining treatment strategy at the end of life; (3) assessment of suspension of life support systems (extubation); and (4) strategies for better end-of-life care. While 42.2% of lawyers cited legislature and judiciary and 54.9% cited academic society guidelines as the system that should respond to the withdrawal and withholding of life-prolonging treatment, 23.3% of doctors cited the legislature and the judiciary, and 65.4% academic society guidelines. In relation to current end-of-life care, 81.3% of lawyers and 69.3% of doctors responded that there was room for improvement. Strategies for doing so included ensuring the transparency of and publishing decision procedures, and notification to government. It is important for medical institutions to normalize end-of-life care by making decisions with reference to guidelines and the like, ensuring the transparency of decision-making procedures, and being managed by a public institution
UR - http://www.scopus.com/inward/record.url?scp=85125268809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125268809&partnerID=8YFLogxK
U2 - 10.18999/nagjms.84.1.139
DO - 10.18999/nagjms.84.1.139
M3 - Article
C2 - 35392001
AN - SCOPUS:85125268809
VL - 84
SP - 139
EP - 147
JO - Nagoya Journal of Medical Science
JF - Nagoya Journal of Medical Science
SN - 0027-7622
IS - 1
ER -